January 2015

New Product - Xtandi

Xtandi (enzalutamide) is an androgen receptor signalling inhibitor that competitively inhibits binding of androgens to androgen receptors, and consequently inhibits the nuclear translocation of these receptors and inhibits the binding of androgen receptor to DNA. Xtandi is indicated for the treatment of patients with metastatic castration resistant prostate cancer who have previously received docetaxel. Xtandi is contraindicated in women who are, or may become, pregnant. Xtandi 40 mg capsules are available in 112’s (carton of 4 wallets, each wallet containing blisters of 28’s).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629